Relish Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2012
For the nine months, the company reported net sales of INR 35.604 million against INR 62.090 million a year ago. Loss from operations before other income, finance cost and exceptional items was INR 6.141 million against profit from operations before other income, finance cost and exceptional items of INR 5.011 million a year ago. Loss from ordinary activities before tax was INR 6.141 million against profit from ordinary activities before tax of INR 5.011 million a year ago. Net loss for the period was INR 6.141 million against net profit for the period of INR 5.011 million a year ago. Basic and diluted loss per share before and after extraordinary items was INR 0.07 against basic and diluted earnings per share before and after extraordinary items of INR 0.06 a year ago.